Among them, the CellSearch® system, based on detection of a cell surface marker of CTCs, epithelial cell adhesion molecule (EpCAM), staining with 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain and antibodies against cytokeratins and CD45, has already been cleared by the US Food and Drug Administration for the detection of circulating tumor cells in metastatic breast, colon and prostate cancer [20,21]. This evidence concerns the gene EPCAM and prostate carcinoma.